ニュース · QuantAbundancia

Simply Wall St.1d agoneutral

Assessing Tempus AI (TEM) Valuation After Recent Share Price Weakness

Recent share performance and business profile Tempus AI (TEM) has drawn investor attention after a period in which the stock fell 22% over the past month and 17% over the past 3 months, while its core healthcare technology operations remain focused on clinical and research applications. See our latest analysis for Tempus AI. At a share price of $43.62, Tempus AI has seen its recent momentum fade, with the share price return down 10% over the past week, 22% over the past month and 30% year to...

Simply Wall St.2d agoneutral

Tempus AI And BMS Deepen AI Drug Development Ties As Losses Persist

Tempus AI and Bristol Myers Squibb are expanding their collaboration to apply AI analytics and real world data to oncology and neuroscience drug development. The partnership focuses on using Tempus AI's multimodal patient data to inform clinical trial design, including programs in oncology and Alzheimer's disease. The agreement highlights growing pharmaceutical interest in AI driven tools that can address complex challenges in precision medicine research. Tempus AI, listed as NasdaqGS:TEM,...

24/7 Wall St.2d agoneutral

7 Healthcare AI Stocks Under $50 With Huge Upside Potential

Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product progress is exactly the kind of setup retail investors should scan for: real revenue, real partnerships, and prices low enough that a successful ... 7 Healthcare AI Stocks Under $50 With Huge Upside Potential

ABCL HIMS SDGR TEM

Simply Wall St.11d agoneutral

Tempus AI Expands Beyond Oncology With New Alzheimer’s Blood Test Alliance

Tempus AI (NasdaqGS:TEM) and Lucent Diagnostics, a Quanterix company, are teaming up to bring an AI-enabled care pathway and blood test for Alzheimer's detection into clinical workflows. The collaboration centers on integrating the LucentAD Complete blood-based biomarker panel into Tempus's Next platform for use by neurologists. The partnership extends Tempus AI's reach beyond oncology into neurology and broader precision medicine applications. Tempus AI, trading at around $49.43 per share,...

TEM

MT Newswires12d agoneutral

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid Employment Data

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.6% and the actively trad

GLD IGV IVV IWM QQQ SOXX SPY TEM+4

MarketBeat14d agoneutral

Tempus AI Q1 Earnings Call Highlights

Tempus AI (NASDAQ:TEM) reported first-quarter 2026 revenue of $348.1 million, up a little over 36% year over year, as the company posted growth across both its diagnostics and data and applications segments and raised its full-year outlook. Founder and CEO Eric Lefkofsky said diagnostics revenue ca

TEM

Moby14d agoneutral

Tempus AI, Inc. Q1 2026 Earnings Call Summary

Moby summary of Tempus AI, Inc.'s Q1 2026 earnings call

TEM

24/7 Wall St.16d agoneutral

Can Nancy Pelosi’s Favorite AI Stock Hope to Regain Its Momentum?

Investors are watching Tempus AI (NASDAQ:TEM) ahead of first-quarter results due after the close tomorrow. The stock burst into investor consciousness in January 2025 after Nancy Pelosi disclosed a position, ran past $100, and has since shed nearly half its value. From Pelosi Halo to Show-Me Story Pelosi’s market-beating track record has turned her trades ... Can Nancy Pelosi’s Favorite AI Stock Hope to Regain Its Momentum?

NVDA QQQ TEM

Insider Monkey19d agoneutral

Tempus AI (TEM) Partners with Keck Medicine of USC to Integrate AI Across Healthcare Network

Tempus AI Inc. (NASDAQ:TEM) is one of the best up and coming stocks with highest upside potential. On April 23, Tempus AI and the Keck School of Medicine of USC launched a multi-faceted collaboration aimed at integrating artificial intelligence and data-driven insights into Southern California’s healthcare landscape. This partnership will impact over 1.5 million annual […]

TEM

Simply Wall St.20d agoneutral

Assessing Tempus AI (TEM) Valuation After A Recent Share Price Bounce

Tempus AI (TEM) has been drawing attention after recent share price moves, with the stock showing a gain over the past month but a decline across the past 3 months and year to date. See our latest analysis for Tempus AI. The recent 10.61% 1 month share price return contrasts with a 16.38% 3 month share price decline and a 19.79% year to date share price loss. Recent momentum therefore appears more like a short term bounce than a sustained trend, even though the 1 year total shareholder return...

TEM

Simply Wall St.20d agoneutral

Tempus AI’s TIME Honor And USC Deal Test Its Long Term Thesis

Tempus AI (NasdaqGS:TEM) was named to TIME’s 10 Most Influential Health and Life Science Companies of 2026. The company expanded its clinical and research reach through a multi year collaboration with the Keck School of Medicine of USC and Keck Medicine of USC. The partnership is aimed at advancing AI driven precision medicine and applying Tempus tools across patient care and research programs. Tempus AI focuses on applying artificial intelligence to precision medicine, with products that...

TEM

Zacks21d agoneutral

TruBridge (TBRG) Earnings Expected to Grow: What to Know Ahead of Q1 Release

TruBridge (TBRG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TEM